Abstract: TH-PO1059
Inflammatory Cytokines and Adipokines in Obese Patients with and Without CKD
Session Information
- CKD Progression and Complications: Diagnosis, Prognosis, Risk Factors
November 02, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Mahajan, Sandeep, All India Institute of Medical Sciences, New Delhi, Delhi, India
- Subbiah, Arunkumar, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background
Global epidemic of obesity & metabolic disorders are fuelling increasing cases of CKD worldwide. Besides having higher incidence of DM & hypertension, obesity is independent risk factor for CKD. Mechanisms involved are poorly studied, though obesity related inflammation mediated by shift in adipokine and cytokine production towards pro-inflammatory state is implicated.
We in this case control study looked at important pro-inflammatory mediators (leptin, IL-6, TNF-α) and anti-inflammatory mediators (adiponectin, IL-10) in obese with & without CKD, non-obese CKD & healthy controls.
Methods
50 consenting subjects in each group were studied. Besides detailed history, co-morbidity charting, BMI calculation; serum levels of HsCRP, adipokines (leptin & adiponectin) & cytokines (IL-6, TNF-α & IL-10) were assessed using commercially available ELISA kits.
Results
Table shows demographic, clinical & study parameters of each group. Patient groups had similar representation of DM & were slightly older than controls. Obese subjects with & without CKD had higher HsCRP, leptin & IL6 than controls & CKD patients, with obese patients with CKD showing maximum aberrations. Adiponectin concentration was higher in patients with obesity alone but suppressed in patients with obesity & CKD.
Conclusion
Inflammation & pro-inflammatory milieu as evidenced by high levels of Hs-CRP, IL-6 & leptin and low levels of adiponectin might be important drivers for obesity related complications like CKD. Larger, prospective studies are required to confirm the same.
Demographic, clinical & study parameters of each group
| Parameter | Control | Obese without CKD | Obese with CKD | Non-obese CKD |
| Age (yr) | 45.7±13.7 | 51.1±12.7* | 50.4±10.8* | 49.7±12.2* |
| Male (%) | 68 | 70 | 68 | 72 |
| DM (%) | 0 | 30* | 32* | 28* |
| BMI | 22.4±2.1 | 33.4±5.7*$ | 32.8±6.2*$ | 21.8±1.8^# |
| eGFR (ml/min) | 81.5±26.4 | 84.2±20.8 | 41.2±18.2*^ | 38.9±20.2*^ |
| HsCRP (mg/L) | 1.5±1.4 | 4.2±0.4*#$ | 8.7±2.1*^$ | 2.5±1.1*^# |
| Leptin (ng/ml) | 2.2±0.6 | 4.4±2.7*#$ | 8.8±2.9*^$ | 1.9±0.8^# |
| Adiponectin (pg/ml) | 5.1±1.1 | 35.3±29.1*#$ | 3.4±0.7*^ | 3.9±0.6*^ |
| IL-6 (pg/ml) | 44.9±16.3 | 503.4±153.8*#$ | 894.9±370.1*^$ | 254.3±78.2*^# |
| TNF-α (pg/ml) | 99.1±12.6 | 113.4±16.1# | 136.7±21.2*^$ | 101.3±19.1# |
| IL-10 (pg/ml) | 82.3±35.9 | 128.9±36.9*# | 316.3±126.2*^# | 115.1±18.6*# |
*p<0.05 vs group 1, ^ p<0.05 vs group 2, # p<0.05 vs group 3, $ p<0.05 vs group 4
Funding
- Government Support – Non-U.S.